DIA496.49+0.58 0.12%
SPY736.99+5.41 0.74%
QQQ707.30+12.36 1.78%

ProQR Therapeutics Collaborates With Ginkgo Bioworks Over Access To 50+ Instrument Autonomous Lab Nebula

Benzinga·04/08/2026 12:02:00
Listen to the news

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced its AI strategy to enhance discovery on the Axiomer platform, including a partnership with Ginkgo Bioworks and the formation of an AI Advisory Board.

ProQR's partnership with Ginkgo Bioworks provides ProQR access to Ginkgo's 50+ instrument autonomous lab, Nebula. Ginkgo's autonomous lab removes a main bottleneck in AI-enabled drug discovery by increasing data generation throughput and speed. This capability is expected to increase the scale and speed of experimental data generation, enabling more efficient discovery timelines and improving the ability of ProQR's discovery AI models to predict drug candidates. Ginkgo made a strategic equity investment in ProQR in connection with the partnership.

Contact Us

Contact Number :+852 3852 8500
Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hk
Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hk
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2026 Webull Securities Limited. All rights reserved.